(Q34189947)

English

Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis (English)

1 reference

Europe PubMed Central

31 July 2017

author name string

Benoît Tyl

1

1 reference

Europe PubMed Central

31 July 2017

Meriam Kabbaj

2

1 reference

Europe PubMed Central

31 July 2017

Sara Azzam

3

1 reference

Europe PubMed Central

31 July 2017

Ander Sologuren

4

1 reference

Europe PubMed Central

31 July 2017

Román Valiente

5

1 reference

Europe PubMed Central

31 July 2017

Elizabeth Reinbolt

6

1 reference

Europe PubMed Central

31 July 2017

Kathryn Roupe

7

1 reference

Europe PubMed Central

31 July 2017

Nathalie Blanco

8

1 reference

Europe PubMed Central

31 July 2017

William Wheeler

9

1 reference

Europe PubMed Central

31 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

3 June 2011

1 reference

Europe PubMed Central

31 July 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

31 July 2017

52

1 reference

Europe PubMed Central

31 July 2017

6

1 reference

Europe PubMed Central

31 July 2017

893-903

1 reference

Europe PubMed Central

31 July 2017

Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Pros and cons of the use of antihistamines in managing allergic rhinitis

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

The significance of QT interval in drug development

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Drug induced QT prolongation and torsades de pointes

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Magnitude, mechanism, and reproducibility of QT interval differences between superimposed global and individual lead ECG complexes.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Man versus machine: is there an optimal method for QT measurements in thorough QT studies?

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Comparison of semiautomated and fully automated methods for QT measurement during a thorough QT/QTc study: variability and sample size considerations.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Recommendations for the standardization and interpretation of the electrocardiogram: part I: the electrocardiogram and its technology a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council o

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Rate-corrected QT interval: techniques and limitations

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Bilastine in allergic rhinoconjunctivitis and urticaria

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407191

21 January 2018

Identifiers

10.1177/0091270011407191

1 reference

Europe PubMed Central

31 July 2017

release_p2oe2odkdrhy5jurdlgpuyyh7e

1 reference

https://api.fatcat.wiki/v0/release/p2oe2odkdrhy5jurdlgpuyyh7e

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34189947&oldid=1842437367"